"With more than half of the world's population, Asia offers an abundance of patients in nearly every therapeutic area," added Dr. Ross Horsburgh, Vice President, Global Clinical Development - Asia/Pacific. "Furthermore, governments have highlighted biopharmaceutical development as a key pillar to their economies, resulting in much more favorable environments for global clinical development work."
The new Kendle offices are located at:
Kendle Sdn Bhd Level 16, 1 Sentral Jalan Stesen Sentral 5 KL Sentral, 50470 Kuala Lumpur Malaysia Kendle C.R.O. (Thailand) Co., Ltd. 23/F M Thai Tower, All Seasons Place 87 Wireless Road Lumpini, Phatumwan Bangkok 10330 Thailand Kendle CRO Philippines, Inc. 18th Floor Philamlife Tower 8767 Paseo de Roxas Makati City 1226, Philippines
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Additional information and investor kits are available
|SOURCE Kendle International Inc.|
Copyright©2009 PR Newswire.
All rights reserved